| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jingdun Xie, Haitao Wang, Ting Lin, Bingtian B. Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer's Disease. BioMed research international. vol 2017. 2018-02-16. PMID:28473983. |
the main hallmarks of alzheimer's disease (ad) are extracellular deposits of amyloid plaques and intracellular accumulation of hyperphosphorylated neurofibrillary tangles (tau). |
2018-02-16 |
2023-08-13 |
Not clear |
| Claire L Russell, Vikram Mitra, Karl Hansson, Kaj Blennow, Johan Gobom, Henrik Zetterberg, Mikko Hiltunen, Malcolm Ward, Ian Pik. Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates. Journal of Alzheimer's disease : JAD. vol 55. issue 1. 2018-02-15. PMID:27636850. |
aberrant tau phosphorylation is a hallmark in alzheimer's disease (ad), believed to promote formation of paired helical filaments, the main constituent of neurofibrillary tangles in the brain. |
2018-02-15 |
2023-08-13 |
human |
| Piotr Lewczuk, Natalia Lelental, Ingolf Lachmann, Max Holzer, Katharina Flach, Sebastian Brandner, Sebastiaan Engelborghs, Charlotte E Teunissen, Henrik Zetterberg, José Luis Molinuevo, Barbara Mroczko, Kaj Blennow, Julius Popp, Lucilla Parnetti, Davide Chiasserini, Armand Perret-Liaudet, Philipp Spitzer, Juan Manuel Maler, Johannes Kornhube. Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. Journal of Alzheimer's disease : JAD. vol 55. issue 1. 2018-02-15. PMID:27662295. |
non-phosphorylated tau as a potential biomarker of alzheimer's disease: analytical and diagnostic characterization. |
2018-02-15 |
2023-08-13 |
Not clear |
| Bettina Maria Foidl, Patricia Do-Dinh, Bianca Hutter-Schmid, Harald R Bliem, Christian Humpe. Cholinergic neurodegeneration in an Alzheimer mouse model overexpressing amyloid-precursor protein with the Swedish-Dutch-Iowa mutations. Neurobiology of learning and memory. vol 136. 2018-02-15. PMID:27670619. |
alzheimer's disease (ad) is a chronic neurodegenerative disorder that is mainly characterized by beta-amyloid (aβ) plaque deposition, tau pathology and dysfunction of the cholinergic system causing memory impairment. |
2018-02-15 |
2023-08-13 |
mouse |
| Chandra Sekhar Kuruva, P Hemachandra Redd. Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal. Drug discovery today. vol 22. issue 2. 2018-02-15. PMID:27794478. |
multiple cellular changes have been identified as being involved in alzheimer's disease (ad) pathogenesis, including mitochondrial damage, synaptic loss, amyloid beta (aβ) production and/or accumulation, inflammatory responses, and phosphorylated tau formation and/or accumulation. |
2018-02-15 |
2023-08-13 |
Not clear |
| Adam M Franks, Regina Guzzo, Shawndra Barker, Rebecca King-Mallor. Progressive Supranuclear Palsy - A Case Study from the Perspective of a Primary Care Physician Son. The West Virginia medical journal. vol 113. issue 1. 2018-02-15. PMID:29373002. |
progressive supranuclear palsy (psp) is a rare geriatric pathology, from the abnormal deposition of the tau protein, combining the motor tremor and bradykinesia of parkinson's disease with the cognitive defects of alzheimer's disease. |
2018-02-15 |
2023-08-13 |
Not clear |
| Joana B Pereira, Eric Westman, Oskar Hansso. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. Neurobiology of aging. vol 58. 2018-02-14. PMID:28692877. |
the aggregation and deposition of amyloid-β (aβ) peptides into plaques is an early event in alzheimer's disease (ad), which is followed by different aspects of neurodegeneration that can be measured in the cerebrospinal fluid (csf) or plasma using neurofilament light (nfl), neurogranin (ng), total tau (t-tau), and phosphorylated tau (p-tau) levels. |
2018-02-14 |
2023-08-13 |
human |
| Jieyun Sun, Xiong Zhang, Chen Wang, Zhipeng Teng, Yu L. Curcumin Decreases Hyperphosphorylation of Tau by Down-Regulating Caveolin-1/GSK-3β in N2a/APP695swe Cells and APP/PS1 Double Transgenic Alzheimer's Disease Mice. The American journal of Chinese medicine. vol 45. issue 8. 2018-02-14. PMID:29132216. |
curcumin decreases hyperphosphorylation of tau by down-regulating caveolin-1/gsk-3β in n2a/app695swe cells and app/ps1 double transgenic alzheimer's disease mice. |
2018-02-14 |
2023-08-13 |
mouse |
| Jieyun Sun, Xiong Zhang, Chen Wang, Zhipeng Teng, Yu L. Curcumin Decreases Hyperphosphorylation of Tau by Down-Regulating Caveolin-1/GSK-3β in N2a/APP695swe Cells and APP/PS1 Double Transgenic Alzheimer's Disease Mice. The American journal of Chinese medicine. vol 45. issue 8. 2018-02-14. PMID:29132216. |
in our previous studies, curcumin has been confirmed to play a neuroprotective role in alzheimer's disease (ad), but its effects on caveolin-1, tau and their correlation, and the mechanism is still unknown. |
2018-02-14 |
2023-08-13 |
mouse |
| T Nishikawa, T Takahashi, M Nakamori, N Hosomi, H Maruyama, Y Miyazaki, Y Izumi, M Matsumot. The identification of raft-derived tau-associated vesicles that are incorporated into immature tangles and paired helical filaments. Neuropathology and applied neurobiology. vol 42. issue 7. 2018-02-12. PMID:26501932. |
neurofibrillary tangles (nfts), a cardinal pathological feature of neurodegenerative disorders, such as alzheimer's disease (ad) are primarily composed of hyper-phosphorylated tau protein. |
2018-02-12 |
2023-08-13 |
Not clear |
| Mari Kim, Manivannan Subramanian, Yun-Ho Cho, Gye-Hyeong Kim, Eunil Lee, Joong-Jean Par. Short-term exposure to dim light at night disrupts rhythmic behaviors and causes neurodegeneration in fly models of tauopathy and Alzheimer's disease. Biochemical and biophysical research communications. vol 495. issue 2. 2018-02-12. PMID:29217196. |
the accumulation and aggregation of phosphorylated tau proteins in the brain are the hallmarks for the onset of alzheimer's disease (ad). |
2018-02-12 |
2023-08-13 |
human |
| Saima Zafar, Neelam Younas, Susana Correia, Mohsin Shafiq, Waqas Tahir, Matthias Schmitz, Isidre Ferrer, Olivier Andréoletti, Inga Zer. Strain-Specific Altered Regulatory Response of Rab7a and Tau in Creutzfeldt-Jakob Disease and Alzheimer's Disease. Molecular neurobiology. vol 54. issue 1. 2018-02-08. PMID:26768426. |
strain-specific altered regulatory response of rab7a and tau in creutzfeldt-jakob disease and alzheimer's disease. |
2018-02-08 |
2023-08-13 |
Not clear |
| Lary C Walker, Mathias Jucke. The Exceptional Vulnerability of Humans to Alzheimer's Disease. Trends in molecular medicine. vol 23. issue 6. 2018-02-08. PMID:28483344. |
nevertheless, the complete behavioral and pathologic phenotype of alzheimer's disease, including aβ plaques, neurofibrillary (tau) tangles, and dementia, has not yet been identified in a non-human species. |
2018-02-08 |
2023-08-13 |
monkey |
| Roberto Piacentini, Domenica Donatella Li Puma, Marco Mainardi, Giacomo Lazzarino, Barbara Tavazzi, Ottavio Arancio, Claudio Grass. Reduced gliotransmitter release from astrocytes mediates tau-induced synaptic dysfunction in cultured hippocampal neurons. Glia. vol 65. issue 8. 2018-02-02. PMID:28519902. |
in alzheimer's disease (ad) misfolded tau accumulates intraneuronally and leads to axonal degeneration. |
2018-02-02 |
2023-08-13 |
Not clear |
| Sarah L DeVos, Rebecca L Miller, Kathleen M Schoch, Brandon B Holmes, Carey S Kebodeaux, Amy J Wegener, Guo Chen, Tao Shen, Hien Tran, Brandon Nichols, Tom A Zanardi, Holly B Kordasiewicz, Eric E Swayze, C Frank Bennett, Marc I Diamond, Timothy M Mille. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Science translational medicine. vol 9. issue 374. 2018-02-01. PMID:28123067. |
accumulation of hyperphosphorylated tau directly correlates with cognitive decline in alzheimer's disease and other primary tauopathies. |
2018-02-01 |
2023-08-13 |
mouse |
| Eleanor K Pickett, Christopher M Henstridge, Elizabeth Allison, Rose Pitstick, Amy Pooler, Susanne Wegmann, George Carlson, Bradley T Hyman, Tara L Spires-Jone. Spread of tau down neural circuits precedes synapse and neuronal loss in the rTgTauEC mouse model of early Alzheimer's disease. Synapse (New York, N.Y.). vol 71. issue 6. 2018-02-01. PMID:28196395. |
spread of tau down neural circuits precedes synapse and neuronal loss in the rtgtauec mouse model of early alzheimer's disease. |
2018-02-01 |
2023-08-13 |
mouse |
| Eleanor K Pickett, Christopher M Henstridge, Elizabeth Allison, Rose Pitstick, Amy Pooler, Susanne Wegmann, George Carlson, Bradley T Hyman, Tara L Spires-Jone. Spread of tau down neural circuits precedes synapse and neuronal loss in the rTgTauEC mouse model of early Alzheimer's disease. Synapse (New York, N.Y.). vol 71. issue 6. 2018-02-01. PMID:28196395. |
synaptic dysfunction and loss is the strongest pathological correlate of cognitive decline in alzheimer's disease (ad) with increasing evidence implicating neuropathological tau protein in this process. |
2018-02-01 |
2023-08-13 |
mouse |
| Marie Sarazin, Julien Lagarde, Michel Bottlaende. Distinct tau PET imaging patterns in typical and atypical Alzheimer's disease. Brain : a journal of neurology. vol 139. issue Pt 5. 2018-01-31. PMID:27189580. |
distinct tau pet imaging patterns in typical and atypical alzheimer's disease. |
2018-01-31 |
2023-08-13 |
Not clear |
| Zhongyun Chen, Chunyan Liu, Jie Zhang, Norman Relkin, Yan Xing, Yanfeng L. Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis. Fluids and barriers of the CNS. vol 14. issue 1. 2018-01-31. PMID:28486988. |
the purpose of this systematic review and meta-analysis was to evaluate the performance of cerebrospinal fluid (csf) beta amyloid 42 (aβ42), total tau (t-tau), and phosphorylated tau (p-tau) as potential diagnostic biomarkers for idiopathic normal-pressure hydrocephalus (inph) and to assess their utility indistinguishing patients with inph from those with alzheimer disease (ad) and healthy normal controls. |
2018-01-31 |
2023-08-13 |
Not clear |
| Andrew J Doig, Maria P Del Castillo-Frias, Olivia Berthoumieu, Bogdan Tarus, Jessica Nasica-Labouze, Fabio Sterpone, Phuong H Nguyen, Nigel M Hooper, Peter Faller, Philippe Derreumau. Why Is Research on Amyloid-β Failing to Give New Drugs for Alzheimer's Disease? ACS chemical neuroscience. vol 8. issue 7. 2018-01-30. PMID:28586203. |
the two hallmarks of alzheimer's disease (ad) are the presence of neurofibrillary tangles (nft) made of aggregates of the hyperphosphorylated tau protein and of amyloid plaques composed of amyloid-β (aβ) peptides, primarily aβ1-40 and aβ1-42. |
2018-01-30 |
2023-08-13 |
Not clear |